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ABSTRACT
Objectives To study the responsiveness of a combined
power Doppler and greyscale ultrasound (PDUS) score for
assessing synovitis in biologic-naïve patients with
rheumatoid arthritis (RA) starting abatacept plus
methotrexate (MTX).
Methods In this open-label, multicentre, single-arm
study, patients with RA (MTX inadequate responders)
received intravenous abatacept (∼10 mg/kg) plus MTX
for 24 weeks. A composite PDUS synovitis score,
developed by the Outcome Measures in Rheumatology–
European League Against Rheumatism (OMERACT–
EULAR)-Ultrasound Task Force, was used to evaluate
individual joints. The maximal score of each joint was
added into a Global OMERACT–EULAR Synovitis Score
(GLOESS) for bilateral metacarpophalangeal joints
(MCPs) 2–5 (primary objective). The value of GLOESS
containing other joint sets was explored, along with
clinical efficacy.
Results Eighty-nine patients completed the 24-week
treatment period. The earliest PDUS sign of improvement
in synovitis was at week 1 (mean change in GLOESS
(MCPs 2–5): −0.7 (95% CIs −1.2 to −0.1)), with
continuous improvement to week 24. Early improvement
was observed in the component scores (power Doppler
signal at week 1, synovial hyperplasia at week 2, joint
effusion at week 4). Comparable changes were observed
for 22 paired joints and minimal joint subsets. Mean
Disease Activity Score 28 (C reactive protein) was
significantly reduced from weeks 1 to 24, reaching
clinical meaningful improvement (change ≥1.2) at
week 8.
Conclusions In this first international prospective
study, the composite PDUS score is responsive to
abatacept. GLOESS demonstrated the rapid onset of
action of abatacept, regardless of the number of joints
examined. Ultrasound is an objective tool to monitor
patients with RA under treatment.
Trial registration number NCT00767325.
INTRODUCTION
Synovitis is the first manifestation of rheumatoid
arthritis (RA), which ultimately leads to joint
erosion.1 Recommendations for management of RA
have evolved to include early aggressive therapy to
prevent or delay permanent structural damage of
the joints.2 3 This has fuelled a search for more
accurate methods to monitor early changes in
synovitis.
Power Doppler and greyscale ultrasound (termed
PDUS in this paper) is a promising, non-invasive
imaging method to assess synovitis in RA: results
from numerous studies suggest that it provides add-
itional information to clinical and conventional
radiographic examinations.4–8 PDUS has demon-
strated similar sensitivity and specificity to MRI in
detecting synovitis,9 10 and may provide a less
daunting option for patients and a more accessible
alternative to MRI in clinical practice. PDUS is also
able to evaluate multiple joints in a short period of
time.
Various scoring systems have been proposed for
the evaluation of synovitis by PDUS, at both indi-
vidual joint and patient levels.11 Such scoring
systems vary with respect to the definition of
ultrasound-detected synovitis and Doppler and
greyscale methods used, and there is no consensus
regarding the number and specific joints evaluated.
Regardless, data from published studies indicate
that PDUS scoring systems could be useful in moni-
toring early response to biological treatment in
patients with RA, independently of the correlation
with other clinical outcomes.12–20
The Outcome Measures in Rheumatology-
Ultrasound (OMERACT-US) Task Force, with
funding received from the European League
Against Rheumatism (EULAR), works to standard-
ise the use of ultrasonography in RA and has devel-
oped a composite scoring system (the OMERACT–
EULAR composite PDUS score) to detect and score
synovitis. This score combines greyscale-assessed
synovial hyperplasia (SH) with intrasynovial power
Doppler (PD) signal for evaluating synovial activity.
The score has demonstrated validity and intraobser-
ver and interobserver reliability in cross-sectional
datasets, applicability to all joints and consistency
between machines.21–24
This report presents data from the first prospective
international study designed to assess the capability
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of the composite PDUS score to measure the early effect and time
course of response to treatment with abatacept in biologic-naïve
patients with active RA despite methotrexate (MTX). The
primary objective of this study was to investigate the responsive-
ness of the composite PDUS score, as defined by an improvement
in the global score (Global OMERACT–EULAR Synovitis Score,
or GLOESS) of the bilaterally evaluated second to fifth metacar-
pophalangeal joints (MCPs 2–5). Other study objectives included
the responsiveness of GLOESS with the full set of 22 paired
joints, in order to then identify the minimum subset of joints (ie,
reduced set) that can adequately monitor disease activity at the
patient level, and the clinical efficacy and safety of abatacept plus
MTX in this patient population.
METHODS
Study design
APPRAISE (NCT00767325) was a 24-week, phase IIIb, open-
label, multicentre, single-arm study conducted at 21 sites across
Europe (Denmark, France, Germany, Hungary, Italy, Norway,
Spain and the UK).
All patients received intravenous abatacept at a weight-tiered
dose of 10 mg/kg at baseline (day 1), and at weeks 2, 4, 8, 12,
16, 20 and 24, in addition to stable doses of concomitant MTX
(≥15 mg/week). MTX dose increases were not permitted, and
MTX dose decreases were allowed only in cases of intolerance.
Oral corticosteroid use (stable dose of ≤10 mg prednisone/day)
was permitted. Patients could take non-steroidal anti-
inflammatory drugs or other rescue analgesics if required,
except in the 12 h before each visit. Concomitant biological
agents or other disease-modifying antirheumatic drugs were not
permitted.
The study was approved by the Institutional Review Board/
Independent Ethics Committee and local ethics committees, and
was conducted in accordance with the ethical principles under-
lying the European Union Directive 2001/20/EC and the United
States Code of Federal Regulations on good clinical practice, as
defined by the International Conference on Harmonisation. All
patients provided written informed consent.
Patients
Eligible patients were ≥18 years of age, had American College
of Rheumatology (ACR), defined RA (1987 classification cri-
teria) for at least 6 months and were receiving MTX (≥15 mg/
week) for at least 3 months prior to baseline, with a stable MTX
dose for at least 28 days before baseline (except in cases of
intolerance). Patients were required to have active disease,
defined by a baseline Disease Activity Score (DAS28 (C reactive
protein, CRP)) of >3.2 or tender joint count (TJC) and swollen
joint count (SJC) of ≥6 and a CRP level of greater than the
upper normal limit. Patients previously treated with a biological
disease-modifying antirheumatic drug were excluded.
Assessments
PDUS assessment
At screening and baseline, all patients underwent a bilateral
PDUS examination of MCPs 2–5. An OMERACT–EULAR com-
posite PDUS score of ≥2 for at least two MCPs and ≥1 for at
least one other MCP joint was required for inclusion. At base-
line, and weeks 1, 2, 4, 6, 8, 12, 16, 20 and 24, PDUS was per-
formed bilaterally for 22 joint sites (MCPs 1–5, proximal
interphalangeal joints (PIPs) 1–5, wrist, elbow, shoulder (gleno-
humeral), knee, ankle (tibiotalar), hind foot (talonavicular and
calcaneocuboidal) and metatarsophalangeal joints (MTPs) 1–5).
Medium-level to high-level ultrasound machines were used
(Esaote Technos MPX, MyLab 70, Toshiba Aplio, GE Logic
(series 5, 7 and 9) or Siemens Acuson Antares), employing high-
frequency (12–18 MHz) transducers. Doppler parameters were
adjusted according to the device used (range of pulse repetition
frequency 400–800 Hz; Doppler frequency 7–11.1 MHz).
PDUS evaluation was performed at each site by an independent
expert in musculoskeletal ultrasound, blinded from clinical eva-
luations. There were no changes in ultrasound settings during
the study, and no upgrading of software. Centres were advised
to create a fixed study setting, to be used at each evaluation. All
images were recorded, anonymised and sent for central reading;
this allowed random verification of the constancy of settings
over time.
The PDUS assessment consisted of an evaluation of hypoe-
choic SH using greyscale and of synovial vascularisation using
PD. The prespecified set of 22 paired joints was scanned at each
visit on the dorsal aspect, with the joint in a neutral position,
except for the knee, which was also examined in a flexed pos-
ition (30°). Standardised joint and probe positions were used,
based on a reference atlas, which also showed examples of syno-
vitis grading for each joint examined.
The presence of synovitis (ie, SH with or without PD) was
scored according to the OMERACT–EULAR PDUS composite
semiquantitative scale (0–3; box 1).21 GLOESS scores for MCPs
2–5 of both hands (primary efficacy assessment) and for the 22
paired joints were then calculated using the sum of the compos-
ite PDUS scores for all joints examined, giving a potential score
of 0–24 for MCPs 2–5 and of 0–132 for the 22 paired joints.
Each single component of joint inflammation (SH, PD) was also
scored separately at each visit, using semiquantitative scales
(0–3; box 1). Joint effusion ( JE) was also scored separately
using a semiquantitative scale (see online supplementary data).
The completion of a training session and examinations was
required by all PDUS assessors in order to be qualified for
PDUS evaluation in this study and ensure homogeneity of syno-
vitis scoring. Quality control assessment of the scoring for
MCPs 2–5 was performed for the first patient from each centre
and at the end of the study using a randomised sample of
images from each site. In cases of discordance, centralised read-
ings were used.
Clinical evaluations
Disease activity was evaluated at baseline (day 1), weeks 1, 2, 4,
6, 8, 12, 16, 20 and 24 using DAS28. Mean change in DAS28
from baseline, the proportion of patients achieving clinically
meaningful improvements (CMIs) in DAS28 (defined as
improvement from baseline of ≥1.2), and the proportions of
patients achieving a DAS28 <2.6, DAS28 ≤3.2 or achieving
ACR/EULAR Boolean remission22 (TJC28 ≤1, SJC28 ≤1, CRP
≤1 mg/dL and patient global assessment (0–10 scale) ≤1) were
calculated.
Safety evaluations
Adverse events (AEs), serious AEs and events of special interest
(infections, serious infections, autoimmune events, malignancies
and acute infusion reactions) were assessed in all patients receiv-
ing at least one dose of study drug, and included events occur-
ring up to 56 days after the last infusion.
Statistical analysis
This was an exploratory study, and therefore, the sample size
was not based on statistical power calculation. No data were
available from longitudinal multicentre studies using the
OMERACT–EULAR composite PDUS score. Based on similar
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studies using ultrasound to measure responsiveness to biological
agents in patients with RA, the sample size was set at 100
patients; the width of the 95% CI of the estimated improvement
in GLOESS for MCPs 2–5 was estimated to be <0.98 on each
side of the interval.
All patients with a PDUS examination at baseline and with at
least one postbaseline efficacy assessment were included in the
efficacy analyses. The time point with the earliest sign of
improvement in synovitis (defined as the time point for which
‘0’ was not included in the 95% CIs for the mean change from
baseline in GLOESS (MCPs 2–5) at that and all later time
points) was recorded. Last observation carried forward was
applied for patients who discontinued prior to week 24.
Descriptive statistics were provided by time point for changes
from baseline in GLOESS and for all efficacy and safety vari-
ables. For continuous data, time point estimates, SE and two-
sided 95% CIs were calculated. For categorical data, frequencies
and percentages were provided. Proportions and two-sided 95%
CIs were calculated for dichotomous categorical data.
Principal component analysis (PCA) was used to identify a
reduced set of joints that best represented the GLOESS for the
22 paired joints. The PCA was performed separately at baseline,
week 12 and week 24 to identify two good subsets at each time
point, explaining at least 75% of the total variation of the
GLOESS over the three time points.23 The best subset was iden-
tified using the efficiency measure criteria. Effect size, expressed
as standardised response means (SRMs) of GLOESS and compo-
nents, was investigated for each of the joint sets based on mean
changes from baseline to week 24.
RESULTS
Patient disposition and baseline characteristics
One hundred and four patients were enrolled in this study. The
majority of patients were female, with long disease duration and
high disease activity, in addition to ultrasound evidence of syno-
vitis at baseline (table 1). Eighty-nine patients (86%) completed
the 24-week open-label treatment period (figure 1).
PDUS findings
Owing to compliance issues (major deviation owing to the lack
of participation in PDUS training), patients from one site (n=8)
were excluded, and PDUS analyses performed using data from
the remaining 96 patients. Figure 2A–C shows the responsive-
ness of PDUS throughout the study period. The earliest PDUS
sign of improvement in synovitis was observed as early as week
1; with a mean (95% CI) change from baseline in GLOESS
(MCPs 2–5) of −0.7 (−1.2 to −0.1). In the assessment of indi-
vidual joint synovitis, the composite PDUS score and PD signal
showed similar trends, with statistically significant reductions by
week 1. SH showed significant reduction by week 2 and JE
showed a first statistically significant sign of improvement at
week 4. Continued improvements in GLOESS (MCPs 2–5) and
in each of the component scores were observed up to week 24
(figure 2A). However, smaller improvements were observed for
JE over the 24-week treatment period compared with GLOESS,
PD and SH scores (figure 2A). Similar trends in the component
Table 1 Baseline demographics and clinical characteristics
Abatacept+MTX (N=104)
Mean age (SD), years 56 (14)
Female, % 84
Caucasian, % 97
Mean disease duration (SD), years 7 (9)
Mean tender joint count (SD) 20 (12)
Mean swollen joint count (SD) 13 (8)
Mean high-sensitivity CRP (SD), mg/dL 1.4 (1.9)
Mean DAS28 (CRP)* (SD) 5.3 (1.1)
Mean GLOESS† (MCPs 2–5) (SD) 12.6 (4.1)
Mean dose of MTX, mg/week 16
Concomitant corticosteroid use, % 53
Concomitant NSAID use, % 43
*n=103.
†n=96 (excludes patients from one site that experienced technical and quality issues
with PDUS scoring and compliance issues).
CRP, C reactive protein; DAS, Disease Activity Score; GLOESS, Global OMERACT–EULAR
(Outcome Measures in Rheumatology–European League Against Rheumatism) Synovitis
Score; MCP, metacarpophalangeal joint; MTX, methotrexate; NSAID, non-steroidal
anti-inflammatory drug; PDUS, power Doppler and greyscale ultrasound.
Box 1 Ultrasound scoring systems at joint and patient
levels
Joint level (for individual joints)
A) Single components
▸ Greyscale inflammatory (hypoechoic) synovial hyperplasia
▸ Grade 0: no hypoechoic synovial hyperplasia
▸ Grade 1: minimal hypoechoic synovial hyperplasia (filling
the angle between the periarticular bones, without
bulging over the line linking tops of the bones)
▸ Grade 2: hypoechoic synovial hyperplasia bulging over
the line linking tops of the periarticular bones but
without extension along the bone diaphysis
▸ Grade 3: hypoechoic synovial hyperplasia bulging over
the line linking tops of the periarticular bones and with
extension to at least one of the bone diaphyses
PD signal
▸ Grade 0: no flow in the hypoechoic synovial
hyperplasiaGrade 1: up to three single spots signals or
up to two confluent spots or one confluent spot plus up
to two single spots
▸ Grade 2: vessel signals in less than half of the area of
the synovium (≤50%)
▸ Grade 3: vessel signals in more than half of the area of
the synovium (>50%)
B) Composite score
OMERACT–EULAR composite PDUS synovitis score
▸ Grade 0 (normal joint): no greyscale-detected synovial
hyperplasia and no PD signal
▸ Grade 1 (minimal synovitis): grade 1 synovial hyperplasia
and ≤ grade 1 PD signal
▸ Grade 2 (moderate synovitis): grade 2 synovial
hyperplasia and ≤ grade 2 PD signal; or grade 1 synovial
hyperplasia and a grade 2 PD signal
▸ Grade 3 (severe synovitis): grade 3 synovial hyperplasia
and ≤ grade 3 PD signal; or grade 1 or 2 synovial
hyperplasia and a grade 3 PD signal
Patient level
Global OMERACT–EULAR Synovitis Score
▸ Sum of composite PDUS scores for all joints assessed (eg,
for MCPs 2–5, global PDUS score would range from 0 to
24)MCP, metacarpophalangeal joint; OMERACT–EULAR,
Outcome Measures in Rheumatology–European League
Against Rheumatism; PD, power Doppler; PDUS, PD and
greyscale ultrasound.
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scores were observed when using the full 22 paired joint evalu-
ation (data not shown).
Reduced joint set
In our population, the reduced joint set that best represented
the composite PDUS score for 22 paired joints over three time
points (baseline, week 12 and week 24), determined by PCA,
comprised nine paired joints (including both large and small
joints: shoulder, elbow, wrist, MCP1, MCP4, PIP2, knee, MTP3
and MTP5). Similar onset and time course of improvement in
GLOESS were observed for the 22-paired, nine-paired and
MCP (2–5) joint sets (figure 2A–C).
To assess the consistency of this new reduced joint set, its
responsiveness was compared with reduced joint sets reported
by Naredo et al24 and Backhaus et al.25 The Backhaus (unilat-
eral) joint set was adapted to be assessed bilaterally in this study,
as the dominant hand was not known during PDUS assessment.
Mean changes from baseline to week 24 in the nine paired joint
GLOESS and components, and the associated SRM were com-
parable with the other two reduced joint sets (table 2).
Clinical efficacy assessments
Clinical efficacy analyses were carried out for all 104 patients.
Mean DAS28 was significantly reduced by week 1, and contin-
ued to decrease throughout the 24-week study period (figure
2D), reaching the threshold for CMI at week 8. In patients with
DAS28 measurements available at both week 12 and week 24
(n=98), the proportion of patients achieving DAS28 ≤3.2 or
DAS28 <2.6 increased over the 24-week treatment period:
40% (39/98) and 19% (19/98), respectively, at week 12, com-
pared with 57% (56/98) and 41% (40/98) at week 24.
Furthermore, the more stringent ACR/EULAR Boolean criteria
for remission were achieved by 11% of patients at week 24,
with an additional 22% of patients achieving three of the four
criteria for Boolean remission at week 24.
No correlations were observed at any time point between
changes from baseline in DAS28, in GLOESS or component
scores for any joint set, or using just the 28 joints used for
DAS28 (see online supplementary material for data). At all time
Figure 2 Mean change in (A) GLOESS and the component scores for metacarpophalangeal joints 2–5, (B) GLOESS for the 22-paired joint set, (C)
GLOESS for the reduced (nine-paired) joint set and (D) DAS28 (CRP) >24 weeks of treatment with abatacept plus methotrexate. Error bars represent
95% CIs. Data are for patients with baseline and at least one postbaseline assessment, with last observation carried forward. PDUS analyses were
completed for 96 of the 104 patients, as patients from one site (n=8) were excluded due to compliance issues. (A) CI did not cross zero from week
1 for GLOESS: −0.7 (−1.2 to −0.1) or power Doppler: −0.9 (−1.5 to −0.3); CI did not cross zero from week 2 for synovial hyperplasia: −1.0 (−1.6
to −0.4); CI did not cross zero from week 4 for joint effusion: −0.8 (−1.4 to −0.3). (B) CI did not cross zero from week 1 −1.7 (−3.4 to −0.1).
(C) CI did not cross zero from week 2 −1.5 (−2.4 to −0.6). (D) CI did not cross zero from week 1 −0.5 (−0.7 to −0.4). CMI, clinically meaningful
improvement (ie, improvement from baseline in DAS28 score of ≥1.2); CRP, C reactive protein; DAS, disease activity score; GLOESS, Global
OMERACT–EULAR (Outcome Measures in Rheumatology–European League Against Rheumatism) Synovitis Score; PDUS, power Doppler and
greyscale ultrasound.
Figure 1 Patient disposition for all patients who received at least one
dose of study drug (N=104). Owing to compliance issues (major
deviation due to the lack of participation in training), patients from one
site (n=8) were excluded before power Doppler and greyscale
ultrasound analyses were performed.
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points, for any joint set, correlations were also very low
between GLOESS or the scoring of each single component and
the SJC and TJC (either separate or combined, see online
supplementary material). However, we observed the same trend
in response whatever the measure used (PDUS or DAS): the
higher the PDUS, GLOESS and DAS at baseline, the less fre-
quently Low Disease Activity Score (LDAS) or low GLOESS
were achieved at 6 months. This was also seen for changes over
time in both measures when expressed as continuous variables.
Safety
AEs were reported in 60% of the total population, of which
21% were assessed as possibly, probably or certainly related to
study drug. Safety with abatacept was consistent with previous
findings, with no unexpected AEs, deaths or opportunistic infec-
tions reported. A safety summary is in the online supplementary
material.
DISCUSSION
This was the first international multicentre study to document
the responsiveness of PDUS in patients with RA starting treat-
ment with abatacept plus MTX. It also validated the composite
PDUS scoring system in this setting. The responsiveness of this
scoring system was able to show statistically significant improve-
ment as early as week 1. The same responsiveness was observed
using DAS28, although changes in mean DAS28 did not reach
the threshold for CMI until week 8.
The composite score incorporates both PD and greyscale mea-
sures of synovitis, evaluating changes in both activity and
morphology of synovitis. Both PD and SH scores contributed to
responsiveness. As expected, JE showed the lowest sensitivity to
change following treatment, with the earliest sign of improve-
ment observed at week 4. This is in agreement with the idea
that effusion alone does not reflect a principal part of synovial
activity and is less responsive to treatment. Therefore, JE was
not included in the calculation of the OMERACT–EULAR com-
posite PDUS score.
This study has limitations. First, the single-arm design pre-
cludes an assessment of the efficiency of PDUS in comparing
treatment groups with different levels of response; such an
assessment can be performed only within a randomised clinical
trial. Second, the open label design could lead to bias from a
positive expectation of response. However, such an expectation
would likely affect clinical measurements more strongly than
ultrasound, leading to larger clinical improvements compared
with ultrasound—a phenomenon not seen in this study. Other
factors that might influence the response would influence both
measurement modalities, and thus not affect the comparison
between clinical and ultrasound response. Furthermore, the
sample size of 100 patients, extrapolated from a previous longi-
tudinal study using a similar ultrasound scoring system 16 and
the decision to analyse GLOESS in MCPs 2–5 as the primary
efficacy outcome (owing to their frequent involvement in RA),
may have resulted in suboptimal power. As discussed, the sensi-
tivity of synovitis scores based on greyscale and/or PD signal can
be affected by variables relating to the technology used, and by
factors such as ambient temperature, transducer pressure26 and
patient positioning.27 Clinical characteristics may also be rele-
vant; for example, a low level of inflammation at baseline might
make it harder to measure response to treatment. Finally,
although several joint sets were compared in this study, the
influence of using different joints with more or less PD activity
(eg, MCP vs talocrural joint) on GLOESS remains unclear.
This study has identified a new reduced set of nine paired
joints to represent the comprehensive 22 paired joint GLOESS.
Onset and time course of improvement of this new set was
similar to other sets, including previously published reduced
joint sets.24 25 Of note, we adapted a previously published
7-joint score (which evaluated only the dominant side)25 to a
bilateral paired joint set, which may have increased its sensitivity.
If confirmed, bilateral evaluation of a reduced joint set could
replace a full-body assessment, making such evaluation more
suitable for use in routine clinical practice.25
The early onset of response to treatment with abatacept (1 week)
in biologic-naïve patients with RA is in agreement with findings
from the ASSET (IM101-119: Impact of intravenous Abatacept on
Synovitis, osteitis and Structural damage in patients with rheuma-
toid arthritis and an inadequate response to mEthotrexate: a rando-
mized controlled Trial) and AMPLE (IM101-235: Abatacept versus
adaliMumab comParison in bioLogic-naïvE rheumatoid arthritis
(RA) subjects with background methotrexate) studies.28 29 The
safety profile is consistent with the long-term profile demonstrated
for the pooled intravenous abatacept clinical trial experience,30 and
no new safety signals were identified.
In conclusion, this study documents the responsiveness of the
OMERACT–EULAR composite PDUS score in biologic-naïve
patients with RA starting abatacept, with changes detectable as
early as week 1. A newly proposed nine-paired joint set worked as
well as a 22-paired joint set for monitoring disease. An accompany-
ing article explores these data further, by investigating if the com-
posite PDUS score can be used to predict clinical response in this
patient population, and if it can differentiate between early and late
clinical responders. Further work is also required to test the PDUS
scoring system and proposed joint count in other RA cohorts.
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